ACRV
Acrivon Therapeutics, Inc. Common Stock$1.81-0.14 (-7.40%)Prev Close$1.96·MCap$52.7M·P/E—·Vol271.7K·Yield—
▲
Buys (12M)
6
$228.7K
▼
Sells (12M)
22
$231.9K
◆
Net Activity
Net Seller
$3.2K
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Acrivon Therapeutics, Inc. Common Stock (ACRV) has been mixed between buying and selling, with 6 insider purchases totaling $228.7K and 22 insider sales totaling $231.9K. The most recent insider transaction was by Blume-Jensen Peter (director, officer: President and CEO), who sold $31.0K worth of shares on Aug 27, 2026. Acrivon Therapeutics, Inc. Common Stock operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $52.7M.
ACRV Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Blume-Jensen Peter | director, officer: President and CEO | Sell | 14,036 | $2.21 | $31.0K | 2,230,052 |
| Aug 20, 2026 | Gamelin Erick | officer: Chief Development Officer | Sell | 400 | $2.01 | $804.00 | 52,592 |
| Aug 20, 2026 | Peterson Katharine | officer: Chief Accounting Officer | Sell | 101 | $2.01 | $203.01 | 18,033 |
| Aug 20, 2026 | Blume-Jensen Peter | director, officer: President and CEO | Sell | 1,713 | $2.01 | $3.4K | 2,244,088 |
| Aug 20, 2026 | Miller Mary | officer: Chief Legal Officer | Sell | 185 | $2.01 | $371.85 | 82,009 |
| Aug 20, 2026 | Devroe Eric | officer: Chief Operating Officer | Sell | 604 | $2.01 | $1.2K | 146,349 |
| Aug 6, 2026 | Levy Adam D. | officer: Chief Financial Officer | Sell | 1,142 | $1.57 | $1.8K | 66,008 |
| Jul 23, 2026 | Miller Mary | officer: Chief Legal Officer | Sell | 573 | $1.76 | $1.0K | 82,194 |
| Feb 14, 2026 | Blume-Jensen Peter | President and CEO | Sell | 1,881 | $1.63 | $3.1K | 0 |
| Feb 14, 2026 | Devroe Eric | Chief Operating Officer | Sell | 723 | $1.63 | $1.2K | 0 |
| Feb 14, 2026 | Gamelin Erick | Chief Development Officer | Sell | 471 | $1.63 | $767.73 | 0 |
| Feb 14, 2026 | Miller Mary | Chief Legal Officer | Sell | 217 | $1.63 | $353.71 | 0 |
| Feb 14, 2026 | Peterson Katharine | Chief Accounting Officer | Sell | 116 | $1.63 | $189.08 | 0 |
| Jan 17, 2026 | Miller Mary | Chief Legal Officer | Sell | 659 | $1.98 | $1.3K | 0 |
| Jan 16, 2026 | Blume-Jensen Peter | director, officer: President and CEO | Buy | 49,000 | $1.68 | $82.1K | 2,095,771 |
| Jan 16, 2026 | Levy Adam D. | officer: Chief Financial Officer | Buy | 8,832 | $1.70 | $15.0K | 20,983+73% |
| Jan 15, 2026 | Devroe Eric | officer: Chief Operating Officer | Buy | 10,000 | $1.72 | $17.2K | 75,308 |
| Jan 14, 2026 | Blume-Jensen Peter | President and CEO | Buy | 49,000 | $1.68 | $82.1K | 0 |
| Jan 14, 2026 | Levy Adam D. | Chief Financial Officer | Buy | 8,832 | $1.70 | $15.0K | 0 |
| Jan 13, 2026 | Devroe Eric | Chief Operating Officer | Buy | 10,000 | $1.72 | $17.2K | 0 |
| Nov 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,904 | $2.30 | $45.8K | 0 |
| Nov 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 60,255 | $2.24 | $135.0K | 0 |
| Nov 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 613 | $2.24 | $1.4K | 0 |
| Nov 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 403 | $2.24 | $902.72 | 0 |
| Nov 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 184 | $2.24 | $412.16 | 0 |
| Nov 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 99 | $2.24 | $221.76 | 0 |
| Oct 17, 2025 | Miller Mary | Chief Legal Officer | Sell | 558 | $1.81 | $1.0K | 0 |
| Oct 1, 2025 | Miller Mary | Chief Legal Officer | Sell | 284 | $1.81 | $514.04 | 0 |
| Aug 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,905 | $1.32 | $26.3K | 0 |
| Aug 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 60,256 | $1.39 | $83.8K | 0 |
| Aug 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 613 | $1.39 | $852.07 | 0 |
| Aug 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 403 | $1.39 | $560.17 | 0 |
| Aug 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 184 | $1.39 | $255.76 | 0 |
| Aug 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 99 | $1.39 | $137.61 | 0 |
| Aug 1, 2025 | Levy Adam D. | Chief Financial Officer | Sell | 1,164 | $1.26 | $1.5K | 0 |
| Jul 17, 2025 | Miller Mary | Chief Legal Officer | Sell | 558 | $1.32 | $736.56 | 0 |
| May 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,904 | $1.15 | $22.9K | 0 |
| May 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 60,257 | $1.14 | $68.7K | 0 |
| May 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 613 | $1.14 | $698.82 | 0 |
| May 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 403 | $1.14 | $459.42 | 0 |
| May 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 184 | $1.14 | $209.76 | 0 |
| May 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 99 | $1.14 | $112.86 | 0 |
| Apr 17, 2025 | Miller Mary | Chief Legal Officer | Sell | 558 | $1.81 | $1.0K | 0 |
| Feb 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,904 | $5.54 | $110.3K | 0 |
| Feb 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 37,731 | $5.42 | $204.5K | 0 |
| Feb 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 724 | $5.42 | $3.9K | 0 |
| Feb 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 469 | $5.42 | $2.5K | 0 |
| Feb 14, 2025 | Holm-Jorgensen Rasmus | Chief Financial Officer | Sell | 434 | $5.42 | $2.4K | 0 |
| Feb 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 217 | $5.42 | $1.2K | 0 |
| Feb 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 116 | $5.42 | $628.72 | 0 |
Showing 1–50 of 91
1 / 2
ACRV Insider Buying Activity
The following table shows recent insider purchases of Acrivon Therapeutics, Inc. Common Stock (ACRV) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | Blume-Jensen Peter | director, officer: President and CEO | Buy | 49,000 | $1.68 | $82.1K | 2,095,771 |
| Jan 16, 2026 | Levy Adam D. | officer: Chief Financial Officer | Buy | 8,832 | $1.70 | $15.0K | 20,983+73% |
| Jan 15, 2026 | Devroe Eric | officer: Chief Operating Officer | Buy | 10,000 | $1.72 | $17.2K | 75,308 |
| Jan 14, 2026 | Blume-Jensen Peter | President and CEO | Buy | 49,000 | $1.68 | $82.1K | 0 |
| Jan 14, 2026 | Levy Adam D. | Chief Financial Officer | Buy | 8,832 | $1.70 | $15.0K | 0 |
| Jan 13, 2026 | Devroe Eric | Chief Operating Officer | Buy | 10,000 | $1.72 | $17.2K | 0 |
ACRV Insider Selling Activity
The following table shows recent insider sales of Acrivon Therapeutics, Inc. Common Stock (ACRV) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Blume-Jensen Peter | director, officer: President and CEO | Sell | 14,036 | $2.21 | $31.0K | 2,230,052 |
| Aug 20, 2026 | Gamelin Erick | officer: Chief Development Officer | Sell | 400 | $2.01 | $804.00 | 52,592 |
| Aug 20, 2026 | Peterson Katharine | officer: Chief Accounting Officer | Sell | 101 | $2.01 | $203.01 | 18,033 |
| Aug 20, 2026 | Blume-Jensen Peter | director, officer: President and CEO | Sell | 1,713 | $2.01 | $3.4K | 2,244,088 |
| Aug 20, 2026 | Miller Mary | officer: Chief Legal Officer | Sell | 185 | $2.01 | $371.85 | 82,009 |
| Aug 20, 2026 | Devroe Eric | officer: Chief Operating Officer | Sell | 604 | $2.01 | $1.2K | 146,349 |
| Aug 6, 2026 | Levy Adam D. | officer: Chief Financial Officer | Sell | 1,142 | $1.57 | $1.8K | 66,008 |
| Jul 23, 2026 | Miller Mary | officer: Chief Legal Officer | Sell | 573 | $1.76 | $1.0K | 82,194 |
| Feb 14, 2026 | Blume-Jensen Peter | President and CEO | Sell | 1,881 | $1.63 | $3.1K | 0 |
| Feb 14, 2026 | Devroe Eric | Chief Operating Officer | Sell | 723 | $1.63 | $1.2K | 0 |
| Feb 14, 2026 | Gamelin Erick | Chief Development Officer | Sell | 471 | $1.63 | $767.73 | 0 |
| Feb 14, 2026 | Miller Mary | Chief Legal Officer | Sell | 217 | $1.63 | $353.71 | 0 |
| Feb 14, 2026 | Peterson Katharine | Chief Accounting Officer | Sell | 116 | $1.63 | $189.08 | 0 |
| Jan 17, 2026 | Miller Mary | Chief Legal Officer | Sell | 659 | $1.98 | $1.3K | 0 |
| Nov 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,904 | $2.30 | $45.8K | 0 |
| Nov 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 60,255 | $2.24 | $135.0K | 0 |
| Nov 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 613 | $2.24 | $1.4K | 0 |
| Nov 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 403 | $2.24 | $902.72 | 0 |
| Nov 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 184 | $2.24 | $412.16 | 0 |
| Nov 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 99 | $2.24 | $221.76 | 0 |
| Oct 17, 2025 | Miller Mary | Chief Legal Officer | Sell | 558 | $1.81 | $1.0K | 0 |
| Oct 1, 2025 | Miller Mary | Chief Legal Officer | Sell | 284 | $1.81 | $514.04 | 0 |
| Aug 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,905 | $1.32 | $26.3K | 0 |
| Aug 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 60,256 | $1.39 | $83.8K | 0 |
| Aug 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 613 | $1.39 | $852.07 | 0 |
| Aug 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 403 | $1.39 | $560.17 | 0 |
| Aug 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 184 | $1.39 | $255.76 | 0 |
| Aug 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 99 | $1.39 | $137.61 | 0 |
| Aug 1, 2025 | Levy Adam D. | Chief Financial Officer | Sell | 1,164 | $1.26 | $1.5K | 0 |
| Jul 17, 2025 | Miller Mary | Chief Legal Officer | Sell | 558 | $1.32 | $736.56 | 0 |
| May 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,904 | $1.15 | $22.9K | 0 |
| May 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 60,257 | $1.14 | $68.7K | 0 |
| May 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 613 | $1.14 | $698.82 | 0 |
| May 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 403 | $1.14 | $459.42 | 0 |
| May 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 184 | $1.14 | $209.76 | 0 |
| May 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 99 | $1.14 | $112.86 | 0 |
| Apr 17, 2025 | Miller Mary | Chief Legal Officer | Sell | 558 | $1.81 | $1.0K | 0 |
| Feb 21, 2025 | Blume-Jensen Peter | President and CEO | Sell | 19,904 | $5.54 | $110.3K | 0 |
| Feb 14, 2025 | Blume-Jensen Peter | President and CEO | Sell | 37,731 | $5.42 | $204.5K | 0 |
| Feb 14, 2025 | Devroe Eric | Chief Operating Officer | Sell | 724 | $5.42 | $3.9K | 0 |
| Feb 14, 2025 | Gamelin Erick | Chief Development Officer | Sell | 469 | $5.42 | $2.5K | 0 |
| Feb 14, 2025 | Holm-Jorgensen Rasmus | Chief Financial Officer | Sell | 434 | $5.42 | $2.4K | 0 |
| Feb 14, 2025 | Miller Mary | Chief Legal Officer | Sell | 217 | $5.42 | $1.2K | 0 |
| Feb 14, 2025 | Peterson Katharine | Chief Accounting Officer | Sell | 116 | $5.42 | $628.72 | 0 |
ACRV Insiders
Similar Stocks to ACRV
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B